Form 4: aTYR Pharma GC Granted Stock Options

aTYR Pharma's General Counsel, Nancy Denyes, was granted 412,500 employee stock options with a $0.7127 exercise price, vesting over three years.

Summary

• Nancy Denyes, General Counsel of aTYR Pharma Inc. (ATYR), reported changes in her beneficial ownership.
• She beneficially owns 31,555 shares of Common Stock directly, which includes 2,500 shares acquired on May 15, 2025, and 2,500 shares acquired on November 14, 2025, under the Company's 2015 Employee Purchase Plan.
• She was granted 412,500 employee stock options on January 9, 2026, with an exercise price of $0.7127 per share.
• These options will vest in 36 equal monthly installments beginning February 9, 2026, becoming fully exercisable on January 9, 2029.
• The options have an expiration date of January 9, 2036.
• The options are subject to accelerated vesting upon termination without cause following a change of control of the issuer.

Sentiment

Score: 6

Explanation: The grant of stock options aligns management incentives with long-term shareholder value, which is generally viewed positively, though it also represents potential future dilution.

Positives

• The grant of 412,500 employee stock options to the General Counsel aligns management's long-term incentives with shareholder value.
• The vesting schedule over three years encourages long-term commitment from a key executive.

Future Outlook

The vesting schedule for the granted stock options indicates a future commitment from the General Counsel, with full exercisability by January 9, 2029, and an expiration date of January 9, 2036. This structure aims to incentivize long-term performance and retention.

Industry Context

This Form 4 filing reports a routine insider transaction related to executive compensation, which is a common practice across the biotechnology and pharmaceutical industries to attract and retain key talent and align their interests with long-term company performance.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from increased management alignment with long-term company performance.
• Employees (General Counsel): Increased long-term incentive and potential for personal wealth creation tied to company stock performance.

Next Steps

• The stock options will vest in 36 equal monthly installments beginning February 9, 2026.
• The options will become fully exercisable on January 9, 2029.

Key Dates

Keywords

ATYR Pharma, Stock Options, Insider Transaction, Form 4, Executive Compensation, Nancy Denyes, General Counsel